Cargando…
A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were en...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213584/ https://www.ncbi.nlm.nih.gov/pubmed/37233785 http://dx.doi.org/10.1007/s00259-023-06283-4 |
_version_ | 1785047653877284864 |
---|---|
author | Wang, Guochang Li, Linlin Zhu, Ming Zang, Jie Wang, Jiarou Wang, Rongxi Yan, Weigang Zhu, Lin Kung, Hank F. Zhu, Zhaohui |
author_facet | Wang, Guochang Li, Linlin Zhu, Ming Zang, Jie Wang, Jiarou Wang, Rongxi Yan, Weigang Zhu, Lin Kung, Hank F. Zhu, Zhaohui |
author_sort | Wang, Guochang |
collection | PubMed |
description | PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. RESULTS: [(68)Ga]Ga-P16-093 PET/CT detected more positive tumors than [(68)Ga]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, [(68)Ga]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 ± 10.2 vs. 11.4 ± 8.3, P < 0.001). For normal organs, [(68)Ga]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 ± 6.1 vs. 29.3 ± 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 ± 7.1 vs. 20.9 ± 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 ± 2.6 vs. 7.6 ± 2.1, P < 0.001), liver (SUVmean: 7.0 ± 1.9 vs. 3.7 ± 1.3, P < 0.001), and spleen (SUVmean: 8.2 ± 3.0 vs. 5.2 ± 2.2, P < 0.001) than [(68)Ga]Ga-PSMA-11 PET/CT. CONCLUSION: [(68)Ga]Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than [(68)Ga]Ga-PSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that [(68)Ga]Ga-P16-093 may serve as an alternative agent for detection of PCa. TRIAL REGISTRATION: (68)Ga-P16-093 and (68)Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered). URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332 . |
format | Online Article Text |
id | pubmed-10213584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-102135842023-05-30 A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer Wang, Guochang Li, Linlin Zhu, Ming Zang, Jie Wang, Jiarou Wang, Rongxi Yan, Weigang Zhu, Lin Kung, Hank F. Zhu, Zhaohui Eur J Nucl Med Mol Imaging Original Article PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. RESULTS: [(68)Ga]Ga-P16-093 PET/CT detected more positive tumors than [(68)Ga]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, [(68)Ga]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 ± 10.2 vs. 11.4 ± 8.3, P < 0.001). For normal organs, [(68)Ga]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 ± 6.1 vs. 29.3 ± 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 ± 7.1 vs. 20.9 ± 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 ± 2.6 vs. 7.6 ± 2.1, P < 0.001), liver (SUVmean: 7.0 ± 1.9 vs. 3.7 ± 1.3, P < 0.001), and spleen (SUVmean: 8.2 ± 3.0 vs. 5.2 ± 2.2, P < 0.001) than [(68)Ga]Ga-PSMA-11 PET/CT. CONCLUSION: [(68)Ga]Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than [(68)Ga]Ga-PSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that [(68)Ga]Ga-P16-093 may serve as an alternative agent for detection of PCa. TRIAL REGISTRATION: (68)Ga-P16-093 and (68)Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered). URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332 . Springer Berlin Heidelberg 2023-05-26 /pmc/articles/PMC10213584/ /pubmed/37233785 http://dx.doi.org/10.1007/s00259-023-06283-4 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Wang, Guochang Li, Linlin Zhu, Ming Zang, Jie Wang, Jiarou Wang, Rongxi Yan, Weigang Zhu, Lin Kung, Hank F. Zhu, Zhaohui A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer |
title | A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer |
title_full | A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer |
title_fullStr | A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer |
title_full_unstemmed | A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer |
title_short | A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer |
title_sort | prospective head-to-head comparison of [(68)ga]ga-p16-093 and [(68)ga]ga-psma-11 pet/ct in patients with primary prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213584/ https://www.ncbi.nlm.nih.gov/pubmed/37233785 http://dx.doi.org/10.1007/s00259-023-06283-4 |
work_keys_str_mv | AT wangguochang aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT lilinlin aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zhuming aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zangjie aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT wangjiarou aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT wangrongxi aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT yanweigang aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zhulin aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT kunghankf aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zhuzhaohui aprospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT wangguochang prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT lilinlin prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zhuming prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zangjie prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT wangjiarou prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT wangrongxi prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT yanweigang prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zhulin prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT kunghankf prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer AT zhuzhaohui prospectiveheadtoheadcomparisonof68gagap16093and68gagapsma11petctinpatientswithprimaryprostatecancer |